Status:
COMPLETED
Baduanjin Lower Elevated Blood PreSsure Study
Lead Sponsor:
China National Center for Cardiovascular Diseases
Conditions:
Elevated Blood Pressure
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
The aim of this study is to evaluate the effects of Baduanjin on blood pressure in individuals with high normal blood pressure (SBP 130-139 mmHg, and/or DBP 85-89 mmHg), as well as on glucose and lipi...
Eligibility Criteria
Inclusion
- Age 40 years or older;
- Systolic blood pressure (SBP) \<140 mmHg and diastolic blood pressure (DBP) \<90 mmHg
- SBP 130-139 mmHg, and/or DBP 85-89 mmHg
Exclusion
- Diagnosis of hypertension (SBP≥140 mmHg, and/or DBP ≥90mmHg）
- History of cardiovascular diseases, such as coronary heart disease, heart failure, stroke, and peripheral vascular disease
- Diagnosis of chronic kidney disease, primary aldosteronism, Cushing's syndrome, or pheochromocytoma
- Newly diagnosed cancer or cancer metastasis within 5 years
- History of autoimmune disease
- Having taken antihypertensive drugs or immunoregulators within 2 weeks
- A long-term need for antihypertensive drugs or immunomoregulators
- Unable to maintain moderate intensity exercise due to illness or other reasons
- Pregnant, breastfeeding, or planning to become pregnant within the next 1 year
- Currently taking regular exercise (at least 30 minutes of moderate-intensity exercise at least three times a week)
- Allergic to sports bracelets
- Having participated or been participating in other clinical trials within the last 3 months
- Unable to use smartphones
- Other factors that may affect the follow-up, such as alcohol or substance abuse in the last 12 months, planing to live out of town for a long time, or diagnosis of dementia or cognitive impairment which indicates incapability of completing the study
- Unable to accurately measure blood pressure using the sphygmomanometer provided by the study due to a too large or too small arm circumference
Key Trial Info
Start Date :
June 5 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 11 2025
Estimated Enrollment :
216 Patients enrolled
Trial Details
Trial ID
NCT05397535
Start Date
June 5 2022
End Date
July 11 2025
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuwai Hospital
Beijing, Beijing Municipality, China